Suggestibility Is a Double-Edged Sword in Psychedelic-Assisted Therapy

Suggestibility Is a Double-Edged Sword in Psychedelic-Assisted Therapy

Psychedelics like psilocybin and MDMA don’t just mask symptoms—they cut through rigid neural pathways, wiping out deeply ingrained patterns that keep people stuck. That’s why the field calls it a “psychedelic renaissance.” But here’s what most articles won’t tell you: the same neural plasticity that unlocks healing also makes patients unusually suggestible—like a browser open to arbitrary cookies, ready to let anyone rewrite the memory cache.

You’re not just more open to insight during a psychedelic session. You’re also more vulnerable to influence—especially from the person sitting across from you in the room—or, for that matter, anyone they’ve invited into their mental orbit. Suggestibility isn’t a bug in this system; it’s part of the design. And if therapists ignore that paradox, they risk reshaping the very breakthroughs they’re trying to preserve.

The Psychology Today piece “Managing Suggestibility in Psychedelic-Assisted Therapy” unpacks this tension across all three phases of treatment: preparation, dosing, and integration. What follows isn’t theoretical musings or generic best practices. These are the safeguard protocols being formalized right now in leading clinics—protocols that, if skipped, can literally distort the science itself.

Let’s walk through why a heightened suggestibility state is both the engine of change and the most common source of confounders in PAT (psychedelic-assisted therapy). I’ll pull straight from Sebastian Salicru’s July 2026 article and the cited researchers to show exactly how skilled clinicians are keeping the pendulum from swinging too far one way or the other.

What Exactly Is Suggestibility—and Why Does It Matter in PAT?

In plain terms, suggestibility is the tendency to uncritically adopt others’ ideas, beliefs, or actions without active scrutiny. As Sebastian Salicru quotes the APA (n.d.) and Schumaker (2026), it means bypassing your own critical filters: the capacity to separate fact from fiction gets momentarily scrambled. That’s fine in low-stakes social contexts. It becomes ethically fraught—possibly clinically harmful—in psychedelic-assisted therapy.

Why? Because psychedelics like psilocybin, ketamine, LSD, and MDMA reduce rigid neural activity while ramping up neuroplasticity. The brain enters an open, highly associative state where connections form faster and with fewer pre-existing constraints (Kishon & Cycowicz, 2025). On the surface, that sounds ideal: a clearer slate for new narratives to emerge.

Here’s where the paradox kicks in. The same cognitive flexibility that supports healing simultaneously weakens decision-making capacity, reduces controllability, and limits resistance to external influence (Villiger, 2024). In other words, patients don’t just become more suggestible—they become unusually suggestible. That’s not theoretical; it’s measurable, and it shows up in both clinical outcomes and research confounders.

Stein & Terhune (2025, p. 449) put it bluntly: suggestibility can improve psychotherapy outcomes—but it also “acts as a significant confound in research in therapeutic interventions,” shaping responses unrelated to the substance itself and inflating perceived drug efficacy. That’s why Oliver et al. (2024) argue that attention to suggestibility has moved to the forefront of clinical and ethical discussions in PAT.

Bottom line: if you treat suggestibility as a background variable, you’re treating it wrong. It’s the single most reliable predictor of both therapeutic impact and unintended influence.

Three Flavors of Suggestibility in Clinical Practice

Research distinguishes three types, each with distinct clinical implications:

1. Primary (hypnotic) suggestibility refers to involuntary movement, altered sensory processing, and deep absorption in direct suggestion. Think immediate motor responses or perceptual shifts triggered by explicit cues—this is the most straightforward and easiest to recognize.

2. Secondary suggestibility relies on indirect, nonverbal cues—what clinicians call “set and setting.” It’s the environment whispering to the patient, not the therapist speaking. The lighting, music, seating arrangement, even the tone of a clinician’s pause: all can nudge perception without being said outright.

3. Tertiary (interpersonal) suggestibility happens when clients uncritically accept recommendations due to social pressure or perceived authority. This is especially potent in PAT because the psychedelic experience itself is context-dependent (Villiger, 2024). The therapeutic alliance—how safe the patient feels with the therapist—becomes a conduit for suggestion, whether intended or not.

Clinicians working with PAT need to watch all three layers in real time. A neutral phrase can land as reinforcement; an empathetic nod might unintentionally confirm a narrative the patient isn’t ready to own. That’s why Villiger (2025) insists that interpersonal and contextual suggestibility warrant extra safeguards during each session.

As Kim et al. (2026) point out, heightened vulnerability during PAT means client safety hinges on recognizing these layers—and then designing safeguards around them before the session even begins.

The Hidden Confound: Why Suggestibility Skews Research

Here’s what many newcomers to PAT don’t anticipate: high suggestibility can make a drug look more effective than it actually is—simply because patient responses align with therapist expectations or session framing.

Stein & Terhune (2025) call this the research confound: a phenomenon where outcome measures capture suggestion-induced narratives rather than substance-specific effects. In trials, this inflates effect sizes and muddies comparative analyses (e.g., psilocybin vs. MDMA). Without careful controls, it becomes impossible to tell whether improvement came from the molecule, the message, or both.

That’s not an academic quibble. It’s why The Lancet (2026) warns that the “psychedelic renaissance” risks going off the rails if commercial pressures, unintended medical harm, and cultural agendas override critical thinking. The field is moving fast, but speed without safeguards risks eroding credibility—and exposing patients to avoidable harm.

The takeaway? Treating suggestibility as a clinical variable, not just an ethical footnote, is what keeps the science honest and the outcomes reliable.

Safeguards Before the Session: Preparation Phase

Once a patient is dosed, it’s too late to tighten informed consent. That’s why preparation matters more than most clinicians realize.

Patients need enhanced informed consent—not just a form they sign and forget. Lee et al. (2024) recommend explicit discussion of likely shifts in personality, values, and identity after psychedelic experiences. This means walking through potential vulnerabilities: memory reconsolidation, identity fluidity, and the risk of uncritical adoption of others’ interpretations.

Preparatory sessions should also include:

• Psychoeducation: Clear explanations of how the substance alters decision-making and critical judgment.
• Therapeutic alliance building: Establishing shared intentions before the session—not improvising them in real time.
• Explicit boundary setting: Clarifying what constitutes suggestion vs. support, and inviting the client to name their own non-negotiables.

Wolff et al. (2025) emphasize that these aren’t optional extra steps; they’re the baseline standard for ethical PAT. Clinicians who skip or rush preparation leave themselves—and their patients—exposed to avoidable suggestion risks.

Safeguards During the Session: Dosing Phase

During dosing, the environment is part of the treatment protocol. Every verbal and nonverbal exchange between team members becomes input to the patient’s suggestible brain.

Practical safeguards include:

• Neutral language: Avoiding evaluative or subcultural terminology (e.g., “good” vs. “bad,” “spiritual” vs. “psychedelic”) that could steer the experience.
• Mindful communication among team members: Even side conversations around the patient become part of the setting. Silence, tone, and eye contact all need intentional calibration.
• Therapist self-examination: Before every session, therapists should bracket their own philosophical or religious beliefs—not to suppress them, but to avoid subtle influence during vulnerable moments.

One of the most powerful interventions, per Villiger (2025), is allowing clients to bring a trusted person of their choosing. Not as a passive observer—but as both emotional support and an independent witness to therapist behavior. That third-party check can catch drift before it derails the session.

The goal isn’t sterility; it’s fidelity. You want the patient to feel safe, not sterile.

Safeguards After the Session: Integration Phase

The integration phase is where suggestion can solidify into belief. Without active mitigation, patients walk away with stories—sometimes powerful ones—that are more reflective of the therapist’s worldview than their own.

Genuine integration means:

• Humility over interpretation: Refraining from imposing metaphysical or spiritual frameworks. Let the client’s insights lead.
• Intent review: Revisiting the original goals for the session and checking whether integration practices align—or just sound good.
• Community scaffolding: Identifying supportive relationships and physical spaces where the insights can safely unfold over time (Bathje et al., 2022).
• Regular supervision: Therapists need their own supportive framework to prevent burnout and moral drift (Caporuscio et al., 2025).

This isn’t about “fixing” the client’s experience. It’s about creating conditions where their own meaning-making can thrive without well-intentioned but potentially misleading suggestions from the outside.

The Ethical Bottom Line

Suggestibility in psychedelic-assisted therapy isn’t a secondary concern. It’s the central mechanism of both healing and harm.

Therapists who treat it like a box to check—sign the consent form, nod during set and setting prep, call it “good therapy”—are playing with fire. The stakes are high: distorted research outcomes, unintended influence, and clients walking away with experiences that feel profound but aren’t theirs.

The best clinicians already know this. They’re the ones securing enhanced consent, undergoing specialized training, and committing to regular supervision—not because someone mandated it, but because they’ve seen what happens when suggestibility runs unchecked.

The “psychedelic renaissance” will only last if the field grounds itself in ethical discipline, not just enthusiasm. That starts with treating suggestibility not as a risk to avoid, but as a lever to calibrate—every single session.